We’ve reported ~700% year-over-year revenue growth, expanded ANKTIVA® authorizations in 33 countries, and continued progress in lung cancer.
With additional label expansion plans and global commercialization efforts underway, we remain focused on broadening patient access worldwide.
Read more: https://t.co/JsbIVgWMH7